COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,580 Articles (22,415 medRxiv, 8,165 bioRxiv)

Most recent first Previous |  Page 1293: Articles 12921-12930  | Next

Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants.
Sacramento, C. Q., Fintelman-Rodrigues, N., Dias, S. S. G., Temerozo, J. R., Da Silva, A. d. P. D., da Silva, C. S., Ferreira, A. C., Mattos, M., Soares, V. C., Pereira-Dutra, F., Miranda, M. D., Barreto-Vieira, D. F., da Silva, M. A. N., de Siqueira Santos, S., Torres, M., Rajoli, R. K. R., Paccanaro, A., Owen, A., Bou-Habib, D. C., Bozza, P. T., Souza, T. M. L.
10.1101/2021.07.21.451321 — Posted: 2021-07-21
Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics
Wang, X., Sacramento, C. Q., Jockusch, S., Chaves, O. A., Tao, C., Fintelman-Rodrigues, N., Chien, M., Temerozo, J. R., Li, X., Kumar, S., Xie, W., Patel, D. J., Meyer, C., Garzia, A., Tuschl, T., Bozza, P. T., Russo, J. J., Souza, T. M. L., Ju, J.
10.1101/2021.07.21.453274 — Posted: 2021-07-21
Lung Epithelial Regulation of BCL2 Related Protein A1 (BCL2A1) by Coronaviruses (SARS-CoV) and Type I Interferon Signaling
Chilakamarti, R.
10.1101/2021.07.21.453244 — Posted: 2021-07-21
CoVizu: Rapid analysis and visualization of the global diversity of SARS-CoV-2 genomes
Ferreira, R.-C., Wong, E., Gugan, G., Wade, K., Liu, M., Munoz Baena, L., Chato, C., Lu, B., Olabode, A. S., Poon, A.
10.1101/2021.07.20.453079 — Posted: 2021-07-21
An untargeted metabolomic approach to identify antiviral defense mechanisms in memory leukocytes secreting in vitro IgG anti-SARS-Cov-2
Timperio, A. M., Gevi, F., Fanelli, G., Lelli, V., Zarletti, G., Tiberi, M., De Molfetta, V., Scapigliati, G.
10.1101/2021.07.20.453042 — Posted: 2021-07-21
Cornering an Ever-Evolving Coronavirus: TATX-03, a fully human synergistic multi-antibody cocktail targeting the SARS-CoV-2 Spike Protein with in vivo efficacy
Roodink, I., van Erp, M., Li, A., Potter, S., van Duijnhoven, S. M. J., Kuipers, A. J., Kazemier, B., van Geffen, E., Hemrika, W., Berkeveld, B., Sonnemans, G., de Vries, B. S., Boers, B., Smits, M., Meurs, S., de Pooter, M., Thom, A., Duplantis, B. N., Romijn, R. A., Houser, J. S., Bath, J., Abdiche, Y. N.
10.1101/2021.07.20.452858 — Posted: 2021-07-21
An Orally Available Cathepsin L Inhibitor Protects Lungs Against SARS-CoV-2-Induced Diffuse Alveolar Damage in African Green Monkeys
Frueh, F. W., Maneval, D. C., Bohm, R. P., Dufour, J. P., Blair, R. V., Simpson, S., Powell, K., Aye, P. P., Golden, N. A., ROY, C. J., Spencer, S., Russell-Lodrigue, K., Plante, K. S., Plante, J. A., McKerrow, J. H., Rappaport, J.
10.1101/2021.07.20.453127 — Posted: 2021-07-21
Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants
Kuo, C.-W., Yang, T.-J., Chien, Y.-C., Yu, P.-Y., Hsu, S.-T. D., Khoo, K.-H.
10.1101/2021.07.21.453140 — Posted: 2021-07-21
Discovery of nanobodies against SARS-CoV-2 and an uncommon neutralizing mechanism
Li, D., Li, T., Zhou, B., Luo, Z., Lai, Y., Huang, S., Zhou, Y., Gautam, A., Bourgeau, S., Wang, S., Bao, J., Tan, J., Lavillette, D.
10.1101/2021.07.20.453054 — Posted: 2021-07-21
Integrin activation is an essential component of SARS-CoV-2 infection
Simons, P., Rinaldi, D., Bondu, V., Kell, A., Bradfute, S., Lidke, D., Buranda, T.
10.1101/2021.07.20.453118 — Posted: 2021-07-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).